BRPI1007995A2 - orto-aminoamidas para o tratamento de cãncer. - Google Patents

orto-aminoamidas para o tratamento de cãncer.

Info

Publication number
BRPI1007995A2
BRPI1007995A2 BRPI1007995A BRPI1007995A BRPI1007995A2 BR PI1007995 A2 BRPI1007995 A2 BR PI1007995A2 BR PI1007995 A BRPI1007995 A BR PI1007995A BR PI1007995 A BRPI1007995 A BR PI1007995A BR PI1007995 A2 BRPI1007995 A2 BR PI1007995A2
Authority
BR
Brazil
Prior art keywords
aminoamides
ortho
cancer
treatment
Prior art date
Application number
BRPI1007995A
Other languages
English (en)
Inventor
Liang Chungen
Tang Guozhi
Christopher Wong Jason
Wu Xihan
Zhang Zhenshan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1007995A2 publication Critical patent/BRPI1007995A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1007995A 2009-02-23 2010-02-16 orto-aminoamidas para o tratamento de cãncer. BRPI1007995A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09153445 2009-02-23
EP09157150 2009-04-02
PCT/EP2010/051909 WO2010094678A1 (en) 2009-02-23 2010-02-16 Novel ortho-aminoamides for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI1007995A2 true BRPI1007995A2 (pt) 2019-09-24

Family

ID=42102214

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007995A BRPI1007995A2 (pt) 2009-02-23 2010-02-16 orto-aminoamidas para o tratamento de cãncer.

Country Status (14)

Country Link
US (1) US7977372B2 (pt)
EP (1) EP2398769A1 (pt)
JP (1) JP2012518612A (pt)
KR (1) KR20110117194A (pt)
CN (1) CN102300845A (pt)
AR (1) AR075530A1 (pt)
AU (1) AU2010215524A1 (pt)
BR (1) BRPI1007995A2 (pt)
CA (1) CA2751777A1 (pt)
IL (1) IL213761A0 (pt)
MX (1) MX2011008899A (pt)
SG (1) SG173672A1 (pt)
TW (1) TW201032800A (pt)
WO (1) WO2010094678A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP3524324A1 (en) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
JP6008201B2 (ja) * 2013-05-10 2016-10-19 東レ・ファインケミカル株式会社 スチレン誘導体の製造方法
NZ720508A (en) 2013-11-28 2019-03-29 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
AU2015361018B2 (en) * 2014-12-08 2020-01-16 Fmc Corporation 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones
US12128018B2 (en) 2018-01-12 2024-10-29 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer
AU2019232704B2 (en) 2018-03-05 2024-03-21 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1033046B (it) 1970-10-31 1979-07-10 Finotto Martino Procedimento di fabbricazione di benzimidazoli sostituiti
DE2201062A1 (de) 1972-01-11 1973-07-26 Bayer Ag N-alkoxycarbonyl- bzw. n-alkylthiocarbonyl-2-(2'-thienyl)-benzimidazole, ein verfahren zu ihrer herstellung und ihre verwendung als fungizide
EP1233958B1 (en) 1999-11-23 2011-06-29 MethylGene Inc. Inhibitors of histone deacetylase
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
WO2005030704A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
AU2006240258A1 (en) 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene derivatives
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
AU2007221207A1 (en) 2006-02-28 2007-09-07 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
WO2009138338A1 (en) * 2008-05-16 2009-11-19 F. Hoffmann-La Roche Ag Novel n-(2-amino-phenyl)-acrylamides

Also Published As

Publication number Publication date
MX2011008899A (es) 2011-09-15
JP2012518612A (ja) 2012-08-16
AU2010215524A1 (en) 2011-06-30
AR075530A1 (es) 2011-04-06
TW201032800A (en) 2010-09-16
CN102300845A (zh) 2011-12-28
CA2751777A1 (en) 2010-08-26
US20100216806A1 (en) 2010-08-26
IL213761A0 (en) 2011-07-31
EP2398769A1 (en) 2011-12-28
WO2010094678A1 (en) 2010-08-26
US7977372B2 (en) 2011-07-12
KR20110117194A (ko) 2011-10-26
SG173672A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112012005594A2 (pt) tratamento de câncer
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
EA201171367A1 (ru) Винилиндазолильные соединения
LT2558105T (lt) Bardoksolono metilas, skirtas nutukimo gydymui
PT2456889E (pt) Marcadores para o cancro do endométrio
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1006438A2 (pt) terapia adjuvante de cancer
HUE046667T2 (hu) Rák kombinatív kezelése
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BR112012002797A2 (pt) tratamento de câncer de próstata
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BR112013011659A2 (pt) métodos de tratamento do câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.